Navellier & Associates Inc. Lowers Stake in Hims & Hers Health, Inc. $HIMS

Key Points

• Navellier & Associates cut its stake in Hims & Hers by 87.9% in Q4, selling 81,442 shares and leaving 11,235 shares valued at about $365,000.
• Significant insider selling has occurred recently — insiders sold 204,857 shares worth roughly $5.29 million in the past 90 days (including the CFO's 19,645‑share sale executed under a Rule 10b5‑1 plan) and now own 13.71% of the stock.
• Hims & Hers beat Q4 EPS estimates ($0.08 vs. $0.02) but slightly missed revenue forecasts, the stock trades near $25.68, and the analyst consensus is a "Hold" with a $31.86 average price target amid mixed broker moves.

Navellier & Associates Inc. lessened its holdings in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 87.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,235 shares of the company's stock after selling 81,442 shares during the quarter. Navellier & Associates Inc.'s holdings in Hims & Hers Health were worth $365,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in HIMS. Quent Capital LLC purchased a new stake in shares of Hims & Hers Health during the third quarter worth about $28,000. Flagship Harbor Advisors LLC bought a new stake in shares of Hims & Hers Health in the fourth quarter worth about $28,000. Binnacle Investments Inc purchased a new position in shares of Hims & Hers Health during the third quarter valued at about $28,000. Bogart Wealth LLC increased its position in shares of Hims & Hers Health by 235.8% during the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company's stock valued at $29,000 after buying an additional 632 shares during the period. Finally, Geneos Wealth Management Inc. purchased a new position in shares of Hims & Hers Health during the first quarter valued at about $30,000. Hedge funds and other institutional investors own 63.52% of the company's stock.

Analyst Ratings Changes

Several brokerages recently issued reports on HIMS. Barclays boosted their price target on shares of Hims & Hers Health from $25.00 to $29.00 and gave the company an "overweight" rating in a research report on Wednesday, March 11th. Evercore set a $24.00 price objective on shares of Hims & Hers Health in a research note on Tuesday, February 24th. Morgan Stanley dropped their price objective on shares of Hims & Hers Health from $40.00 to $21.00 and set an "equal weight" rating on the stock in a research note on Tuesday, February 24th. Zacks Research raised shares of Hims & Hers Health from a "strong sell" rating to a "hold" rating in a research note on Wednesday, February 25th. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of Hims & Hers Health in a research note on Friday, March 27th. Four equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Hims & Hers Health has a consensus rating of "Hold" and a consensus price target of $31.86.

Insider Buying and Selling at Hims & Hers Health

In other news, insider Irene Becklund sold 5,529 shares of the business's stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total value of $136,511.01. Following the completion of the sale, the insider owned 8,752 shares in the company, valued at approximately $216,086.88. The trade was a 38.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Oluyemi Okupe sold 19,645 shares of the business's stock in a transaction dated Monday, April 20th. The shares were sold at an average price of $29.96, for a total transaction of $588,564.20. Following the completion of the sale, the chief financial officer owned 262,954 shares of the company's stock, valued at approximately $7,878,101.84. This represents a 6.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 204,857 shares of company stock worth $5,285,706. 13.71% of the stock is owned by company insiders.

Hims & Hers Health Stock Down 4.5%

Shares of HIMS stock opened at $25.68 on Friday. The company has a market capitalization of $5.85 billion, a price-to-earnings ratio of 50.35, a PEG ratio of 3.67 and a beta of 2.43. Hims & Hers Health, Inc. has a one year low of $13.74 and a one year high of $70.43. The company's fifty day moving average price is $22.56 and its 200-day moving average price is $29.75. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.90 and a quick ratio of 1.70.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings data on Monday, February 23rd. The company reported $0.08 EPS for the quarter, topping analysts' consensus estimates of $0.02 by $0.06. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The business had revenue of $617.82 million during the quarter, compared to analysts' expectations of $619.48 million. During the same period last year, the company posted $0.11 EPS. The business's revenue was up 28.4% on a year-over-year basis. Sell-side analysts expect that Hims & Hers Health, Inc. will post 0.53 EPS for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.

The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

Want to see what other hedge funds are holding HIMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims & Hers Health, Inc. (NYSE:HIMS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.